Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

CJC-1295 DAC Dosing Protocol: 2 mg Vial — Weekly Dosing Schedule & Supplies

Complete CJC-1295 DAC protocol for the 2 mg vial — the long-acting GHRH analogue with Drug Affinity Complex for once-to-twice weekly subcutaneous dosing.

Go to peptide profileCalculate your dose

Quickstart highlights

CJC-1295 DAC contains the GHRH 1-29 analogue with a Drug Affinity Complex (DAC) — a maleimidoproprionic acid lysine modification that covalently binds serum albumin in vivo, extending the half-life from ~30 minutes (No DAC) to approximately 6–8 days.

  • Concentration: 2 mg/mL (2 mg vial + 1 mL bacteriostatic water).
  • At 2 mg/mL: 1 mg = 50 units, 2 mg = 100 units (full vial).
  • CJC-1295 DAC half-life: approximately 6–8 days; once-weekly injection maintains GH elevation.
  • Teichman et al. (2006): once-weekly CJC-1295 DAC raised IGF-1 by 35–70% above baseline at 4 weeks.
  • One 2 mg vial provides 1 full dose (2 mg weekly) or 2 half-doses (1 mg biweekly).

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-4100050Once weekly1 mg — 50 units; one 2 mg vial provides 2 weekly doses
5-122000100Once weekly2 mg — 100 units (full vial); reassess after 4 weeks
13+2000100Twice weekly2 mg 2x weekly for maximum GH elevation; 1 vial per injection

Gradual approach

WeekDose (µg)UnitsNotes
1-8500250.5 mg conservative start — 25 units; one 2 mg vial provides 4 doses
9-161000501 mg — 50 units; advance only if well tolerated

Reconstitution steps

  1. Draw 1 mL bacteriostatic water; inject slowly down the vial wall to avoid foaming.
  2. Swirl gently until the lyophilized powder fully dissolves; do not shake.
  3. Final concentration: 2 mg/mL (2,000 µg/mL). At 2 mg/mL: 1 mg = 50 units on a U-100 syringe.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

8-week plan

  • 4 vials
  • 8 syringes
  • 4 mL bac water
  • 8 alcohol swabs

12-week plan

  • 6 vials
  • 12 syringes
  • 6 mL bac water
  • 12 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Achieve sustained GH elevation through the convenient once-weekly CJC-1295 DAC injection protocol, using the 2 mg vial for single or double-dose supply without the complexity of daily GHRH injections.

Cycle length: 12 weeks on.

Off-cycle: 4–6 weeks off after every 12-week cycle; check IGF-1 levels.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days. CJC-1295 DAC binds albumin in vivo after injection, extending half-life to approximately 7–8 days — once-weekly dosing maintains therapeutic GH elevation.

Injection & tracking tips

  • CJC-1295 DAC's 7–8 day half-life provides sustained GH elevation between once-weekly injections — unlike CJC-1295 No DAC (modified GRF 1-29) which requires 2–3 daily injections.
  • Inject at any time of day; DAC's sustained action negates the timing precision required for No-DAC peptides.
  • Do not combine CJC-1295 DAC with daily GHRP injections if IGF-1 rises above 300 ng/mL — monitor every 6 weeks.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Measure IGF-1 at baseline, 6 weeks, and 12 weeks; CJC-1295 DAC raises IGF-1 significantly with once-weekly dosing.
  • Track morning fasting glucose monthly — sustained GH elevation can impair insulin sensitivity.
  • Monitor for water retention (ankle edema, weight gain) in the first 4 weeks — common with DAC-formulation GH peptides.
Log your cycle in the calculator →

How this works & references

CJC-1295 DAC contains the GHRH 1-29 analogue with a Drug Affinity Complex (DAC) — a maleimidoproprionic acid lysine modification that covalently binds serum albumin in vivo, extending the half-life from ~30 minutes (No DAC) to approximately 6–8 days. Once-weekly subcutaneous injection of 1–2 mg raises serum IGF-1 by 35–70% above baseline after 4 weeks of treatment (Teichman et al., 2006), comparable to daily GHRH peptide injections. Combination with GHRP (ipamorelin 200–300 µg 2x daily) produces significantly higher total GH output than DAC alone.

Sources

Frequently asked questions

What is the difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC (with Drug Affinity Complex) binds serum albumin after injection, extending half-life to 6–8 days and enabling once-weekly dosing. CJC-1295 No DAC (modified GRF 1-29) has a 30-minute half-life, requiring injection 2–3x daily alongside a GHRP. DAC is more convenient; No DAC provides more physiological pulsatility.
Should I combine CJC-1295 DAC with a GHRP?
Yes — combining with ipamorelin or GHRP-2 (200–300 µg at least once daily) significantly amplifies GH output versus DAC alone. The GHRH (DAC) + GHRP combination stimulates GH through complementary pituitary pathways, producing 2–4x greater pulse amplitudes.
Is CJC-1295 DAC appropriate for first-time GH peptide users?
CJC-1295 No DAC + ipamorelin is generally preferred for first-time users because the shorter half-life allows dose adjustment. The DAC formulation's 7-day persistence means side effects (water retention, insulin resistance) are harder to manage after injection.
How much IGF-1 increase can I expect?
In the Teichman et al. (2006) trial, CJC-1295 DAC at 30 µg/kg (approximately 1.8–2.4 mg for a 60–80 kg adult) raised mean IGF-1 by 35–70% above baseline, persisting for 6–7 days. Real-world compounding protocols report IGF-1 increases of 40–100 ng/mL at 2 mg weekly when combined with a GHRP.
Can CJC-1295 DAC cause HGHD (growth hormone dependence)?
GHRH analogues do not bypass hypothalamic feedback in the same way exogenous HGH does. Discontinuation of CJC-1295 DAC typically returns IGF-1 to baseline within 2–4 weeks without rebound suppression. Long-term cycling (12 weeks on, 4–6 weeks off) is still recommended to maintain pituitary responsiveness.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →